BetterLife Pharma (BETRF) Amortizatization of Intangibles (2011 - 2026)
BetterLife Pharma (BETRF) posted quarterly Amortizatization of Intangibles of $4781.9 for Q2 2026, down 77.24% year-over-year from $21007.4 in Q2 2025, and down 65.79% quarter-over-quarter from $13976.4 in Q3 2025.
BetterLife Pharma (BETRF) Amortizatization of Intangibles (2011 - 2026) Analysis & Trends
BetterLife Pharma's Amortizatization of Intangibles history runs 14 years deep, the most recent figure standing at $4781.9 for Q2 2026.
- In Q2 2026, Amortizatization of Intangibles fell 77.24% year-over-year to $4781.9; the TTM figure through Apr 2026 stood at -$122213.8 (down 738.96% YoY), while the FY2026 annual figure was $12792.3, up 13.86% from the prior year.
- Amortizatization of Intangibles for Q2 2026 stood at $4781.9, down from $13976.4 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $120092.5 in Q3 2024, with the low at -$161979.4 in Q1 2025.
- The 5-year median for Amortizatization of Intangibles is $14019.6 (2022), against an average of $5380.4.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles surged 1269.27% in 2022, then tumbled 3325.61% in 2023.
- BetterLife Pharma's Amortizatization of Intangibles stood at $13963.2 in 2022, then plunged by 361.36% to -$36494.4 in 2023, then soared by 209.62% to $40006.4 in 2024, then plunged by 65.06% to $13976.4 in 2025, then tumbled by 65.79% to $4781.9 in 2026.
- Business Quant data shows BETRF's Amortizatization of Intangibles at $4781.9 in Q2 2026, $13976.4 in Q3 2025, and $21007.4 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | 4,781.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 4,781.91 |
| Apr 30, 2026 | 4,781.91 |
| Jul 31, 2025 | 13,976.39 |
| Jul 31, 2025 | 13,976.39 |
| Apr 30, 2025 | 21,007.37 |
| Apr 30, 2025 | 21,007.37 |
| Jan 31, 2025 | -161,979.43 |
| Jan 31, 2025 | -161,979.43 |
| Oct 31, 2024 | 40,006.40 |
| Oct 31, 2024 | 40,006.40 |
| Jul 31, 2024 | 120,092.50 |
| Jul 31, 2024 | 120,092.50 |
| Apr 30, 2024 | 19,781.77 |
| Apr 30, 2024 | 19,781.77 |
| Jan 31, 2023 | -36,494.40 |
| Jan 31, 2023 | -36,494.40 |
| Oct 31, 2022 | 13,963.20 |
| Oct 31, 2022 | 13,963.20 |
| Jul 31, 2022 | 14,234.97 |
| Jul 31, 2022 | 14,234.97 |